mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

(2017) Thomas Farge et al.   Cancer Discovery

miR-29b Mediates NF-κB Signaling in KRAS-Induced Non–Small Cell Lung Cancers

(2016) Stephanie Langsch et al.   CANCER RESEARCH

A combinatorial strategy for treating KRAS-mutant lung cancer

(2016) Eusebio Manchado et al.   NATURE

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells

(2015) Akriti Kharbanda et al.   Oncotarget

Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer

(2015) Shigeru Kawabata et al.   Oncotarget

3D cell culture systems modeling tumor growth determinants in cancer target discovery

(2014) Claudio R. Thoma et al.   ADVANCED DRUG DELIVERY REVIEWS

Rapamycin: One Drug, Many Effects

(2014) Jing Li et al.   Cell Metabolism

A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non-Small Cell Lung Cancer

(2014) N. Vasan et al.   CLINICAL CANCER RESEARCH

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin

(2014) Y. Xia et al.   Science Translational Medicine

Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1

(2014) Valentina Pirazzoli et al.   Cell Reports

Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M

(2014) Shigeru Kawabata et al.   Cell Reports

A Rare Population of CD24+ITGB4+Notchhi Cells Drives Tumor Propagation in NSCLC and Requires Notch3 for Self-Renewal

(2013) Yanyan Zheng et al.   CANCER CELL

Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer

(2013) E. M. Coffee et al.   CLINICAL CANCER RESEARCH

Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung Cancer

(2013) Suresh S. Ramalingam et al.   Journal of Thoracic Oncology

Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer

(2013) Balázs Győrffy et al.   PLoS One

TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma

(2013) R. B. Corcoran et al.   Science Translational Medicine

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110  Inhibitors in PIK3CA-Mutant Breast Cancer

(2013) M. Elkabets et al.   Science Translational Medicine

Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis

(2012) Wen Cai Zhang et al.   CELL

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer

(2012) Vassiliki A. Papadimitrakopoulou et al.   Journal of Thoracic Oncology

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy

(2011) M Bartucci et al.   CELL DEATH AND DIFFERENTIATION

Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model

(2011) Johan Vansteenkiste et al.   Journal of Thoracic Oncology

First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review

(2010) John Goffin et al.   Journal of Thoracic Oncology

Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

(2010) Katharine A. Price et al.   Journal of Thoracic Oncology

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

(2009) Anurag Singh et al.   CANCER CELL

TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser2481 Is a Marker for Intact mTOR Signaling Complex 2

(2009) J. Copp et al.   CANCER RESEARCH

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

(2009) Claudia Scholl et al.   CELL

Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non-Small Cell Lung Cancer

(2009) A. Yoshizawa et al.   CLINICAL CANCER RESEARCH

ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays

(2009) Yifang Hu et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Spheroid-based drug screen: considerations and practical approach

(2009) Juergen Friedrich et al.   Nature Protocols

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

(2009) Michel DuPage et al.   Nature Protocols

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment

(2009) G. Bertolini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE